These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20609175)

  • 21. Immunity unleashed in melanoma.
    Erdmann MK
    Lancet Oncol; 2010 Feb; 11(2):108-9. PubMed ID: 20152761
    [No Abstract]   [Full Text] [Related]  

  • 22. Dual fronts poised to transform melanoma therapy.
    Mullard A
    Nat Rev Drug Discov; 2011 May; 10(5):325-6. PubMed ID: 21532549
    [No Abstract]   [Full Text] [Related]  

  • 23. PD-1 inhibitor becomes "breakthrough therapy".
    Cancer Discov; 2013 Jul; 3(7):OF14. PubMed ID: 23847357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patients.
    Weber JS
    Ann Surg Oncol; 2005 Dec; 12(12):957-9. PubMed ID: 16244797
    [No Abstract]   [Full Text] [Related]  

  • 25. Are we entering a new era in melanoma treatment? Lesson from ASCO 2011.
    Mouawad R; Spano JP; Khayat D
    Melanoma Res; 2011 Oct; 21(5):377-9. PubMed ID: 21900791
    [No Abstract]   [Full Text] [Related]  

  • 26. Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression.
    Mosca PJ; Robertson GP
    Cancer Biol Ther; 2011 Mar; 11(6):581-3. PubMed ID: 21282973
    [No Abstract]   [Full Text] [Related]  

  • 27. Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg.
    Damian DL; Thompson JF
    Am J Clin Dermatol; 2011 Dec; 12(6):403-4. PubMed ID: 21967115
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of metastatic melanoma with CTLA4 antibodies].
    Hafner C
    Hautarzt; 2010 Sep; 61(9):808-10. PubMed ID: 20721523
    [No Abstract]   [Full Text] [Related]  

  • 29. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
    Luke JJ; Ott PA
    Expert Opin Pharmacother; 2013 Dec; 14(18):2457-62. PubMed ID: 24138302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant therapy for melanoma: a surgical perspective.
    Sondak VK; Gonzalez RJ; Kudchadkar R
    Surg Oncol Clin N Am; 2011 Jan; 20(1):105-14. PubMed ID: 21111961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Are immunological treatments beneficial for malignant melanoma of the skin?].
    Vihinen P; Vuoristo MS; Hernberg M; Pyrhönen S
    Duodecim; 2010; 126(14):1701-10. PubMed ID: 20804089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [To outwit melanoma with its own tricks].
    Bischoff A
    MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
    [No Abstract]   [Full Text] [Related]  

  • 33. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
    van Rooij N; van Buuren MM; Philips D; Velds A; Toebes M; Heemskerk B; van Dijk LJ; Behjati S; Hilkmann H; El Atmioui D; Nieuwland M; Stratton MR; Kerkhoven RM; Kesmir C; Haanen JB; Kvistborg P; Schumacher TN
    J Clin Oncol; 2013 Nov; 31(32):e439-42. PubMed ID: 24043743
    [No Abstract]   [Full Text] [Related]  

  • 34. Pulmonary sarcoid-like granulomatosis induced by ipilimumab.
    Berthod G; Lazor R; Letovanec I; Romano E; Noirez L; Mazza Stalder J; Speiser DE; Peters S; Michielin O
    J Clin Oncol; 2012 Jun; 30(17):e156-9. PubMed ID: 22547608
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunotherapies in clinical trials: do they demand different evaluation tools?
    Tuma RS
    J Natl Cancer Inst; 2011 May; 103(10):780-1. PubMed ID: 21551417
    [No Abstract]   [Full Text] [Related]  

  • 36. Melanoma: more answers, more questions.
    Urba WJ
    Oncologist; 2013 Jun; 18(6):658-60. PubMed ID: 23814163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.
    Albertini MR; Hank JA; Sondel PM
    Cancer Chemother Biol Response Modif; 2005; 22():789-97. PubMed ID: 16110641
    [No Abstract]   [Full Text] [Related]  

  • 38. Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma.
    Killock D
    Nat Rev Clin Oncol; 2015 Aug; 12(8):438. PubMed ID: 26077044
    [No Abstract]   [Full Text] [Related]  

  • 39. Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).
    Kelderman S; van der Kooij MK; van den Eertwegh AJ; Soetekouw PM; Jansen RL; van den Brom RR; Hospers GA; Haanen JB; Kapiteijn E; Blank CU
    Acta Oncol; 2013 Nov; 52(8):1786-8. PubMed ID: 23607756
    [No Abstract]   [Full Text] [Related]  

  • 40. Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma.
    Matsushita S; Krähenbühl L; Otsuka A; Mihic-Probst D; Cheng P; Dummer R; Goldinger SM
    J Dermatol; 2015 Sep; 42(9):927-8. PubMed ID: 26046957
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.